Focused On-demand Library for Solute carrier family 2, facilitated glucose transporter member 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P14672

UPID:

GLUT4_HUMAN

Alternative names:

Glucose transporter type 4, insulin-responsive

Alternative UPACC:

P14672; Q05BQ3; Q14CX2

Background:

Solute carrier family 2, facilitated glucose transporter member 4, also known as Glucose transporter type 4 (GLUT4), plays a pivotal role in glucose homeostasis. It is an insulin-responsive transporter, crucial for the uptake of glucose into muscle and fat cells. Upon insulin stimulation, GLUT4 translocates to the cell surface, facilitating glucose entry from the bloodstream into cells.

Therapeutic significance:

GLUT4's involvement in Type 2 diabetes mellitus, a condition characterized by insulin resistance and hyperglycemia, underscores its therapeutic potential. Targeting GLUT4's function or its insulin-stimulated translocation mechanism could lead to innovative treatments for managing Type 2 diabetes and its associated metabolic complications.